00825nas a2200289   4500000000100000000000100001008004100002653000900043653003300052653001600085653002200101653003100123100001800154700001400172700001700186700001600203700001500219700001700234700001600251700001600267700001300283245019200296250001500488300001100503490000700514020001400521       2022                            d10aCprd10aImmune checkpoint inhibitors10aLung cancer10aStudy eligibility10aTyrosine kinase inhibitors1 aA. van Veelen1 aS. Abtahi1 aP. Souverein1 aJ. Driessen1 aO. Klungel1 aA. Dingemans1 aR. van Geel1 aF. de Vries1 aS. Croes00aCharacteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors  a2022/04/17  a1021490 v78  a1877-7821